Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients
Conclusions
Pegfilgrastim is commonly used for primary prophylaxis during the first cycle of chemotherapy. Hospitalizations for febrile neutropenia occurred most commonly among patients without primary prophylaxis. Pegfilgrastim-associated bone pain occurred in a similar percentage, as reported in randomized controlled trials but less than that reported by survey. Loratadine was the most commonly employed medication to mitigate this adverse effect.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Pawloski, P. A., Larsen, M., Thoresen, A., Giordana, M. D. Tags: Original Articles Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Filgrastim | Neulasta | Neupogen | Pain | Study